Edwards Lifesciences: +11%

Edwards Lifesciences: +11%

Edwards has certainly had meteoric growth since the beginning of 2014, with its stock rising from the mid-$60 range then to the $155 range in July of this year. Now trading at about $135 per share, Edwards has benefitted from solid sales of its Sapien lines of transcatheter heart valves. Recently, the company's stock has tumbled a bit. Another consideration is that its credit rating is less than ideal: The company has a BBB- credit rating from S&P, reflecting a moderate business risk as of July 22, 2015.